Article
Fluoxazolevir inhibits hepatitis C virus infection in humanized chimeric mice by blocking viral membrane fusion.
Nature microbiology - 1 Dec 2020
Ma Christopher D, Imamura Michio, Talley Daniel C, Rolt Adam, Xu Xin, Wang Amy Q, Le Derek, Uchida Takuro, Osawa Mitsutaka, Teraoka Yuji, Li Kelin, Hu Xin, Park Seung Bum, Chalasani Nishanth, Irvin Parker H, Dulcey Andres E, Southall Noel, Marugan Juan J, Hu Zongyi, Chayama Kazuaki, Frankowski Kevin J, Liang Tsanyang Jake
Abstract excerpt
Fluoxazolevir is an aryloxazole-based entry inhibitor of hepatitis C virus (HCV). We show that fluoxazolevir inhibits fusion of HCV with hepatic cells by binding HCV envelope protein 1 to prevent fusion. Nine of ten fluoxazolevir resistance-associated substitutions are in envelope protein 1, and four are in a putative fusion peptide. Pharmacokinetic studies in mice, rats and dogs revealed that fluoxazolevir...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.